News Releases

May 16, 2017
Synlogic and Mirna Investor Conference Call Information
Synlogic and Mirna Therapeutics will host a conference call to discuss the proposed transaction as well as Synlogic’s platform and pipeline assets on  May 16, 2017 at 8:30 AM ET . The live webcast can be accessed through the information below....
May 16, 2017
Synlogic and Mirna Therapeutics Agree to Merger
– Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines – – Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors – – Combined Company Well-Capitalized with Approximately...
March 23, 2017
Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting
Cambridge, Mass (BUSINESS WIRE).  March 22 nd , 2017.  Synlogic™ Inc. today announced that the company will present preclinical data on two rare metabolic disease programs from its Synthetic Biotics™ platform at the American College of Medical Genetics and Genomics Annual Meeting from...
December 15, 2016
Synlogic Appoints COO and Head of Corporate Development
Experienced biotechnology leader, Sam Truex, joins Synlogic’s leadership team CAMBRIDGE, Mass., December 15, 2016 – CAMBRIDGE, Mass. – Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced...
November 10, 2016
Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia
First Live  E. Coli  Nissle Bacterium Modified to Assimilate Ammonia Potential Treatment of Urea Cycle Disorders and Other Forms of Hyperammonemia CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
September 12, 2016
Synlogic Expands Leadership Team to Support Rapid Advancement of the First Synthetic Biotic Towards the Clinic
Company Appoints Seasoned Biotech Executives to Lead Finance, Clinical, Translational and Manufacturing Functions September 12, 2016 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
August 29, 2016
Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation
The Company Has Developed The First Live  E. Coli  Nissle Bacterium Modified To Assimilate Ammonia For The Potential Treatment Of Urea Cycle Disorders CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
March 23, 2016
Synlogic Appoints an Industry Leader Nick Leschly to its Board of Directors
CAMBRIDGE, Mass., – March 23, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr....
February 17, 2016
Synlogic Secures $40 Million in Series B Financing
Additional funding to accelerate the two lead Urea Cycle Disorder and Phenylketonuria pipeline programs to the clinic and expand the Synthetic Biotics platform CAMBRIDGE, Mass., – February 17, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
February 10, 2016
Synlogic Announces First Industry Collaboration to Develop a New Class of Medicines Designed to Power the Microbiome
Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease  CAMBRIDGE, Mass., – February 10, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and the...
January 5, 2016
Synlogic to Present at the 34th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., – January 5, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced that J.C. Gutiérrez-Ramos, Ph.D., Chief Executive Officer of Synlogic will present at a...
September 17, 2015
Synlogic Accelerates Business Growth with Appointment of President, Expansion of Financing, and an Industry Collaboration
Bharatt Chowrira, Ph.D., J.D., appointed as Synlogic’s President bringing industry expertise in corporate development, strategy, intellectual property and financing Two proprietary rare disease programs being advanced into clinical development with accelerated financing An R&D collaboration...
Displaying 121 - 132 of 136